Cassidy Henegar, PhD, MSPH

Director
ViiV Healthcare

Disclosure(s): GlaxoSmithKline: Stocks/Bonds; ViiV Healthcare: full-time employee

Poster(s):

• 1264 - Durability and effectiveness of fostemsavir in heavily treatment-experienced people with HIV
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 1265 - Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS)
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 1284 - Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET